Skip to main
NVCR
NVCR logo

Novocure (NVCR) Stock Forecast & Price Target

Novocure (NVCR) Analyst Ratings

Based on 16 analyst ratings
Buy
Strong Buy 25%
Buy 44%
Hold 25%
Sell 6%
Strong Sell 0%

Bulls say

NovoCure Ltd has demonstrated significant growth in its financial performance, reporting a fourth-quarter revenue of $161.3 million, which reflects a 4% increase from the previous quarter, and a full-year revenue of $605.2 million, marking a 19% increase compared to 2023. The company's positive outlook is further supported by a strong increase in the probability of success (POS) for its pancreatic cancer treatments, rising from 20% to 70% after favorable trial results, which adds confidence in its pipeline. Additionally, the recent approvals of the new HFE transducer arrays enhance the usability and appeal of the Optune Gio device, potentially increasing patient compliance and leading to improved long-term survival rates, thereby strengthening NovoCure's market position in oncology.

Bears say

NovoCure Ltd has revised its 2025 revenue estimate down to $616.1 million from a prior estimate of $648.1 million, reflecting anticipated low-to-mid single-digit growth that does not account for improvements in approval rates. The company has also reported a 4% decline in prescriptions for its Optune Gio device in the fourth quarter of 2024, indicating potential challenges in product adoption and market penetration. Additionally, there are multiple risks that could negatively impact the company's performance, including safety concerns in clinical programs, lower-than-expected efficacy, increasing competition, regulatory challenges, and issues related to intellectual property protection.

Novocure (NVCR) has been analyzed by 16 analysts, with a consensus rating of Buy. 25% of analysts recommend a Strong Buy, 44% recommend Buy, 25% suggest Holding, 6% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Novocure and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Novocure (NVCR) Forecast

Analysts have given Novocure (NVCR) a Buy based on their latest research and market trends.

According to 16 analysts, Novocure (NVCR) has a Buy consensus rating as of Jul 4, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $77.69, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $77.69, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Novocure (NVCR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.